J.PaulMonkIIIMD

Oncology • Columbus, OH

medical Oncologist and an assistant professor in the Department of Internal Medicine At the OSUCCC

Join to view full profile

Dr. Monk is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Monk's full profile

Already have an account?

Office
460 W 10th Ave
Columbus, OH 43210
Phone+1 614-293-6529

Fax+1 614-293-9469

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1999 - 2002
OhioHealth/Riverside Methodist HospitalResidency, Internal Medicine, 1996 - 1999
Ohio State University College of MedicineClass of 1996

Certifications & Licensure

OH State Medical License 1999 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma Start of enrollment: 2006 Nov 08
Completed
Phase 1
Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer Start of enrollment: 2008 Feb 01
Terminated
Phase 2
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2009 Oct 29
Active, not recruiting
Phase 1, Phase 2
Tivantinib in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2012 Jan 11
Completed
Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

4 citations
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Prog...
Wassim Abida, Andrew W Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber
Clinical Cancer Research. 2024-03-15
Chemotherapy for the initial treatment of metastatic prostate adenocarcinoma and neuroendocrine carcinoma at diagnosis: real world application and impact in the SEER d...
Shihua Wang, Ming Yin, Peng Wang, Edmund Folefac, J Paul Monk
Frontiers in Oncology. 2023-01-01
54 citations
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
James A. Eastham, Glenn Heller, Susan Halabi, J. Paul Monk, Himisha Beltran
Journal of Clinical Oncology. 2020-07-24

Professional Memberships

American Society of Clinical Oncology - ASCO
Member